Drug intelligence / Profile preview

NTHi H99-115

Development stage: Preclinical
Modality: Vaccines & Immunotherapeutics
Administration: Intratracheal

Overview

NTHi H99-115 is a specific strain of Non-typeable Haemophilus influenzae (NTHi) that has been investigated as a killed immunogen in a mouse model. The research focuses on its ability to induce strain-specific pulmonary defense, particularly in the context of acute exacerbations of chronic obstructive pulmonary disease (COPD) caused by NTHi. The outer membrane protein P2 and other surface antigens of NTHi H99-115 are believed to be key components in eliciting this protective immune response.

Targets

OmpP2 (Outer membrane protein P2)

Beyond the preview

Go deeper on NTHi H99-115.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NTHi H99-115.

Explore the full profile